Controversies Continue in NCCN Ovarian Cancer Guidelines Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Tuesday, March 20, 2012

Controversies Continue in NCCN Ovarian Cancer Guidelines



Controversies Continue in NCCN Ovarian Cancer Guidelines

Medscape Medical News from the:  

National Comprehensive Cancer Network (NCCN) 17th Annual Conference

This coverage is not sanctioned by, nor a part of, the National Comprehensive Cancer Network.

From Medscape Medical News > Conference News

Controversies Continue in NCCN Ovarian Cancer Guidelines

Neoadjuvant Chemotherapy and CA-125 Reviewed


 
March 20, 2012 (Hollywood, Florida) — The ovarian cancer guidelines from the National Comprehensive Cancer Network (NCCN) address a number of ongoing controversies, according to a presenter here at the NCCN 17th Annual Conference.
 
"There have not been a lot of changes in the past year, but there are various areas of controversy in the guidelines," Robert Morgan, MD, from the City of Hope Comprehensive Cancer Center in Los Angeles, California, told Medscape Medical News at the conference.
One such controversy is about the usefulness of the biomarker CA-125 to monitor patients who have been treated with surgery and/or chemotherapy. Dr. Morgan called CA-125 the "most controversial" aspect of patient follow-up.......

0 comments :

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.